BioPharmSignal logoBioPharmSignal

Biotech News

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

CVRx (CVRX)CVRxEarnings

MINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to

Related news

STIMNeuronetics2026-10-21 12:30 EST

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

PRCTPROCEPT BioRobotics2026-10-12 20:05 EST

PROCEPT BioRobotics® to Report Third Quarter 2026 Financial Results on November 4th, 2026

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

CVRXCVRx2026-08-25 12:00 EST

CVRx Responds to Letter from Pointillist Family Office

CVRXCVRx2026-08-24 12:30 EST

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Stock data

Close
1.37 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States